Alkahest provided update on their novel multifactorial approach to the treatment of Alzheimer’s Disease
| SAN CARLOS, Calif., Oct. 29, 2018 /PRNewswire/ -- Alkahest, Inc. (“Alkahest”), a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat Alzheimer’s Disease and other age-related diseases, presented on 26-October at the Clinical Trials in Alzheimer’s Disease (CTAD) Conference in Barcelona. Dr. Jonas Hannestad provided an update on Alkahest’s ongoing Randomized, Double-Blind, Safety and Tolerability Study of GRF6019 in Mild-to-Moderate Alzheimer’s Disease. “A growing body of research supports our hypothesis that multiple factors in the plasma proteome play an important modulatory role in the development of age-related diseases, particularly cognitive disorders and neurodegeneration. Alkahest is exploring a unique multi-factorial approach to treating these complex diseases,” said Jonas Hannestad, M.D., Ph.D., Alkahest’s Vice President, Clinical Development. “As the world’s population grows older, the burden of age-related diseases has become one of the greatest medical challenges for biomedical research. Our innovative therapeutics derived from and targeting the plasma proteome are currently in clinical development and are well-positioned to address this critical need,” said Karoly Nikolich, Ph.D., Chief Executive Officer of Alkahest. About Alkahest Contact Information:
SOURCE Alkahest, Inc. |
View original content:
